Advancements and Innovations in Antibody Drug Conjugates
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 31 May 2025
Special Issue Editors
Interests: cancer therapy; drug delivery; drug targeting; infectious disease; micelle; nanoparticles; nanotechnology; polymers; targeted therapies; HIV; antibody engineering; antibody–drug conjugates
Special Issues, Collections and Topics in MDPI journals
Interests: C-H activation; self-immolative linkers; antibody drug conjugates; organic chemistry
Special Issue Information
Dear Colleagues,
Antibody–drug conjugates (ADCs) represent a groundbreaking advancement in targeted cancer therapy, merging the specificity of monoclonal antibodies with a highly potent cytotoxic small-molecule drug. ADCs aim to improve efficacy by reducing side effects through the specific targeting of cancer cells, sparing healthy tissues. Recent innovations in ADC development have focused on optimizing antibody engineering, bispecific antibodies, combination therapies, linker stability, and the choice of payloads to enhance the therapeutic index. Improved conjugation techniques, payload delivery mechanisms, and linker chemistries are advancing the field towards greater efficacy and safety profiles.
This Special Issue highlights the latest advancements and innovations in ADC technology including recent antibody-based drug delivery systems, approved ADCs, clinical development, cytotoxic payload, drug linker design, cleavable linker design, site-specific conjugation, biodistribution, pharmacokinetics, and molecular imaging.
Dr. Murali Mohan Yallapu
Dr. Shivaji Edupuganti
Dr. Ebaston Thankarajan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody–drug conjugates
- monoclonal antibodies
- targeted therapies
- linker technologies
- site-specific conjugation
- bioimaging
- pharmacokinetics
- therapeutic index
- next-generation ADCs
- drug resistance
- bispecific antibodies
- combination therapies
- off-target toxicity
- efficacy and safety
- tumor-specific antigens
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
